{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:28:21Z","timestamp":1794860901829,"version":"4.9.1"},"reference-count":329,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Dopamine regulates several functions, such as voluntary movements, spatial memory, motivation, sleep, arousal, feeding, immune function, maternal behaviors, and lactation. Less clear is the role of dopamine in the pathophysiology of type 2 diabetes mellitus (T2D) and chronic complications and conditions frequently associated with it. This review summarizes recent evidence on the role of dopamine in regulating insular metabolism and activity, the pathophysiology of traditional chronic complications associated with T2D, the pathophysiological interconnection between T2D and chronic neurological and psychiatric disorders characterized by impaired dopamine activity\/metabolism, and therapeutic implications. Reinforcing dopamine signaling is therapeutic in T2D, especially in patients with dopamine-related disorders, such as Parkinson\u2019s and Huntington\u2019s diseases, addictions, and attention-deficit\/hyperactivity disorder. On the other hand, although specific trials are probably needed, certain medications approved for T2D (e.g., metformin, pioglitazone, incretin-based therapy, and gliflozins) may have a therapeutic role in such dopamine-related disorders due to anti-inflammatory and anti-oxidative effects, improvement in insulin signaling, neuroinflammation, mitochondrial dysfunction, autophagy, and apoptosis, restoration of striatal dopamine synthesis, and modulation of dopamine signaling associated with reward and hedonic eating. Last, targeting dopamine metabolism could have the potential for diagnostic and therapeutic purposes in chronic diabetes-related complications, such as diabetic retinopathy.<\/jats:p>","DOI":"10.3390\/biomedicines11112993","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T11:25:31Z","timestamp":1699356331000},"page":"2993","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity\/Metabolism: Implication for Pathophysiological and Therapeutic Purposes"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6521-8578","authenticated-orcid":false,"given":"Giuseppe","family":"Lisco","sequence":"first","affiliation":[{"name":"Interdisciplinary Department of Medicine, School of Medicine, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"De Tullio","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, School of Medicine, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Iovino","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, School of Medicine, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Disoteo","sequence":"additional","affiliation":[{"name":"Diabetology Unit, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Guastamacchia","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, School of Medicine, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7073-1795","authenticated-orcid":false,"given":"Vito Angelo","family":"Giagulli","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, School of Medicine, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6308-0528","authenticated-orcid":false,"given":"Vincenzo","family":"Triggiani","sequence":"additional","affiliation":[{"name":"Interdisciplinary Department of Medicine, School of Medicine, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"ref_1","unstructured":"(2023, August 01). Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Dopamine."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2010.12.017","article-title":"Tyrosine hydroxylase and regulation of dopamine synthesis","volume":"508","author":"Daubner","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Yang, S., Boudier-Rev\u00e9ret, M., Choo, Y.J., and Chang, M.C. (2020). Association between Chronic Pain and Alterations in the Mesolimbic Dopaminergic System. Brain Sci., 10.","DOI":"10.3390\/brainsci10100701"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2013.12.001","article-title":"Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model","volume":"65","author":"Yadav","year":"2014","journal-title":"Neurochem. Int."},{"key":"ref_5","unstructured":"Guzm\u00e1n, F. (2016, November 15). The Four Dopamine Pathways Relevant to Antipsychotics Pharmacology. Available online: http:\/\/psychopharmacologyinstitute.com\/antipsychotics-videos\/dopamine-pathways-antipsychotics-pharmacology\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1210\/jcem-33-6-877","article-title":"Enhancement of insulin secretion in adult onset diabetics by methysergide maleate: Evidence for an endogenous biogenic monoamine mechanism as a factor in the impaired insulin secretion in diabetes mellitus","volume":"33","author":"Quickel","year":"1971","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_7","first-page":"1","article-title":"Insulin secretion. Its regulation by monoamines and acid amyloglucosidase","volume":"372","author":"Lundquist","year":"1971","journal-title":"Acta Physiol. Scand. Suppl."},{"key":"ref_8","first-page":"1797","article-title":"Pancreatic biogenic amines and insulin secretion in health and disease","volume":"32","author":"Lebovitz","year":"1973","journal-title":"Fed. Proc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1210\/endo-87-4-823","article-title":"Effect of catecholamines precursors on insulin secretion","volume":"87","author":"Gagliardino","year":"1970","journal-title":"Endocrinology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1210\/endo-89-5-1295","article-title":"Inhibition of insulin secretion by serotonin and dopamine: Species variation","volume":"89","author":"Quickel","year":"1971","journal-title":"Endocrinology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF00745138","article-title":"Accumulation of dopamine in mouse pancreatic B-cells following injection of L-DOPA. Localization to secretory granules and inhibition of insulin secretion","volume":"13","author":"Ericson","year":"1977","journal-title":"Diabetologia"},{"key":"ref_12","first-page":"56","article-title":"Dopaminergic suppression of pancreatic somatostatin secretion","volume":"101","author":"Itoh","year":"1982","journal-title":"Acta Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1053\/meta.2001.26741","article-title":"Systemic treatment with sympatholytic dopamine agonists improves aberrant \u03b2-cell hyperplasia and GLUT2, glucokinase, and insulin immunoreactive levels in ob\/ob mice","volume":"50","author":"Jetton","year":"2001","journal-title":"Metabolism"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1210\/me.2012-1226","article-title":"Dopamine synthesis and D3 receptor activation in pancreatic \u03b2-cells regulates insulin secretion and intracellular [Ca(2+)] oscillations","volume":"26","author":"Ustione","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/pgmj.56.651.11","article-title":"Effect of bromocriptine on maturity onset diabetes","volume":"56","author":"Barnett","year":"1980","journal-title":"Postgrad. Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Garcia Barrado, M.J., Iglesias Osma, M.C., Blanco, E.J., Carretero Hern\u00e1ndez, M., S\u00e1nchez Robledo, V., Catalano Iniesta, L., Carrero, S., and Carretero, J. (2015). Dopamine modulates insulin release and is involved in the survival of rat pancreatic beta cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123197"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2337\/dc11-2384","article-title":"Circulating dopamine and C-peptide levels in fasting nondiabetic hypertensive patients: The Graz Endocrine Causes of Hypertension study","volume":"35","author":"Tomaschitz","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1210\/me.2012-1101","article-title":"Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitro","volume":"26","author":"Simpson","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1055\/s-0031-1301365","article-title":"Insulin secretion and sensitivity after single-dose amisulpride, olanzapine or placebo in young male subjects: Double blind, cross-over glucose clamp study","volume":"45","author":"Kopf","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/me.2014-1273","article-title":"Anti-incretin, Anti-proliferative Action of Dopamine on \u03b2-Cells","volume":"29","author":"Maffei","year":"2015","journal-title":"Mol. Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Tavares, G., Rosendo-Silva, D., Sim\u00f5es, F., Eickhoff, H., Marques, D., Sacramento, J.F., Capucho, A.M., Sei\u00e7a, R., Conde, S.V., and Matafome, P. (2023). Circulating Dopamine Is Regulated by Dietary Glucose and Controls Glucagon-like 1 Peptide Action in White Adipose Tissue. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032464"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"935872","DOI":"10.3389\/fcdhc.2023.935872","article-title":"Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions","volume":"4","author":"Chien","year":"2023","journal-title":"Front. Clin. Diabetes Healthc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.bbrc.2015.11.002","article-title":"Islet-specific monoamine oxidase A and B expression depends on MafA transcriptional activity and is compromised in type 2 diabetes","volume":"468","author":"Ganic","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_24","unstructured":"(2023, August 31). Available online: https:\/\/www.ncbi.nlm.nih.gov\/gene\/389692."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s00125-007-0712-2","article-title":"Inhibition of MafA transcriptional activity and human insulin gene transcription by interleukin-1beta and mitogen-activated protein kinase kinase kinase in pancreatic islet beta cells","volume":"50","author":"Oetjen","year":"2007","journal-title":"Diabetologia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2337\/diab.30.5.416","article-title":"Characterization of increased plasma dopamine-\u03b2-hydroxylase activity in rats with experimental diabetes","volume":"30","author":"Schmidt","year":"1981","journal-title":"Diabetes"},{"key":"ref_27","first-page":"108","article-title":"Circulating dopamine-\u03b2-hydroxylase in the rat: Importance of altered disposal pathways in experimental diabetes","volume":"220","author":"Hurst","year":"1982","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.6458088","article-title":"Dopamine receptor binding is increased in diabetic rats","volume":"214","author":"Lozovsky","year":"1981","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1159\/000124586","article-title":"Concentration of striatal tyramine and dopamine metabolism in diabetic rats and effect of insulin administration","volume":"43","author":"Kwok","year":"1986","journal-title":"Neuroendocrinology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/BF00964400","article-title":"The concentration of dopamine, 5-hydroxytryptamine, and some of their acid metabolites in the brain of genetically diabetic rats","volume":"10","author":"Kwok","year":"1985","journal-title":"Neurochem. Res."},{"key":"ref_31","first-page":"43","article-title":"Gastrointestinal dopamine as an anti-incretin and its possible role in bypass surgery as therapy for type 2 diabetes with associated obesity","volume":"41","author":"Chaudhry","year":"2016","journal-title":"Minerva Endocrinol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1210\/jcem-44-1-196","article-title":"The effect of dopamine infusion on insulin and glucagon secretion in man","volume":"44","author":"Leblanc","year":"1977","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF00546703","article-title":"The metabolic effects of dopamine in man","volume":"26","author":"Pernet","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0168-8227(90)90026-P","article-title":"Differential effects of dopamine on glucoregulatory hormones in rats","volume":"8","author":"Keck","year":"1990","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.2522\/ptj.20080020","article-title":"Epidemiology of diabetes and diabetes-related complications","volume":"88","author":"Deshpande","year":"2008","journal-title":"Phys. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/archinte.158.2.134","article-title":"The effects of improved glycemic control on complications in type 2 diabetes","volume":"158","author":"Gaster","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11886-019-1123-y","article-title":"The Importance and Role of Multiple Risk Factor Control in Type 2 Diabetes","volume":"21","author":"Mosslemi","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.diabet.2019.01.007","article-title":"Glucocentric risk factors for macrovascular complications in diabetes: Glucose \u2018legacy\u2019 and \u2018variability\u2019-what we see, know and try to comprehend","volume":"45","author":"Monnier","year":"2019","journal-title":"Diabetes Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12933-021-01289-4","article-title":"Variability of risk factors and diabetes complications","volume":"20","author":"Ceriello","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.2337\/dc23-S003","article-title":"Addendum. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes\u20132023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-022-01575-9","article-title":"Cardiovascular outcomes trials: A paradigm shift in the current management of type 2 diabetes","volume":"21","author":"Davies","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"108112","DOI":"10.1016\/j.diabres.2020.108112","article-title":"Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?","volume":"162","author":"Dardano","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gasecka, A., Siwik, D., Gajewska, M., Jaguszewski, M.J., Mazurek, T., Filipiak, K.J., Postu\u0142a, M., and Eyileten, C. (2020). Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092807"},{"key":"ref_44","unstructured":"Kolb, H., Fernandez, E., and Nelson, R. (2020, May 28). Role of Dopamine in Retinal Function, Webvision: The Organization of the Retina and Visual System, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK561740\/."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1184627","DOI":"10.3389\/fopht.2023.1184627","article-title":"Light activation of the dopaminergic system occurs after eye-opening in the mouse retina","volume":"3","author":"Jain","year":"2023","journal-title":"Front. Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2337\/dbi20-0009","article-title":"Dopamine and Early Retinal Dysfunction in Diabetes: Insights From a Phase 1 Study","volume":"69","author":"Wubben","year":"2020","journal-title":"Diabetes"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1125784","DOI":"10.3389\/fnins.2023.1125784","article-title":"Diabetic rats with high levels of endogenous dopamine do not show retinal vascular pathology","volume":"17","author":"Allen","year":"2023","journal-title":"Front. Neurosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e22643","DOI":"10.1096\/fj.202200865R","article-title":"Dopamine ameliorates hyperglycemic memory-induced microvascular dysfunction in diabetic retinopathy","volume":"36","author":"Lee","year":"2022","journal-title":"FASEB J."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Upreti, S., Sen, S., Nag, T.C., and Ghosh, M.P. (2022). Insulin like growth factor-1 works synergistically with dopamine to attenuate diabetic retinopathy by downregulating vascular endothelial growth factor. Biomed. Pharmacother., 149.","DOI":"10.1016\/j.biopha.2022.112868"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"108040","DOI":"10.1016\/j.exer.2020.108040","article-title":"Dopamine metabolite levels in the vitreous of diabetic and non-diabetic humans","volume":"195","author":"Hendrick","year":"2020","journal-title":"Exp. Eye Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2337\/db19-0869","article-title":"Novel Detection and Restorative Levodopa Treatment for Preclinical Diabetic Retinopathy","volume":"69","author":"Motz","year":"2020","journal-title":"Diabetes"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10571-020-00953-9","article-title":"Association Between Pathophysiological Mechanisms of Diabetic Retinopathy and Parkinson\u2019s Disease","volume":"42","author":"Zhang","year":"2022","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12149-022-01818-5","article-title":"18F-FP-CIT dopamine transporter PET findings in the striatum and retina of type 1 diabetic rats","volume":"37","author":"Chen","year":"2023","journal-title":"Ann. Nucl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc20-1815","article-title":"HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression","volume":"44","author":"Bethel","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials","volume":"68","author":"Kapoor","year":"2023","journal-title":"Surv. Ophthalmol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Olivares-Hern\u00e1ndez, A., Figuero-P\u00e9rez, L., Cruz-Hernandez, J.J., Gonz\u00e1lez Sarmiento, R., Usategui-Martin, R., and Miramontes-Gonz\u00e1lez, J.P. (2021). Dopamine Receptors and the Kidney: An Overview of Health- and Pharmacological-Targeted Implications. Biomolecules, 11.","DOI":"10.3390\/biom11020254"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2169\/internalmedicine.0994-18","article-title":"The Relationship between the Intrarenal Dopamine System and Intrarenal Renin-angiotensin System Depending on the Renal Function","volume":"57","author":"Matsuyama","year":"2018","journal-title":"Intern. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/ajh\/hps008","article-title":"Imbalance of renal production between 5-hydroxytryptamine and dopamine in patients with essential hypertension complicated by microalbuminuria","volume":"26","author":"Hirose","year":"2013","journal-title":"Am. J. Hypertens."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.2337\/db12-0046","article-title":"Intrarenal dopamine inhibits progression of diabetic nephropathy","volume":"61","author":"Zhang","year":"2012","journal-title":"Diabetes"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mej\u00eda-Rodr\u00edguez, O., Herrera-Abarca, J.E., Ceballos-Reyes, G., Avila-Diaz, M., Prado-Uribe, C., Belio-Caro, F., Salinas-Gonz\u00e1lez, A., Vega-Gomez, H., Alvarez-Aguilar, C., and Lindholm, B. (2013). Cardiovascular and renal effects of bromocriptine in diabetic patients with stage 4 chronic kidney disease. Biomed. Res. Int., 2013.","DOI":"10.1155\/2013\/104059"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Neumann, J., Hofmann, B., Dhein, S., and Gergs, U. (2023). Role of Dopamine in the Heart in Health and Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24055042"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1474-8673.1982.tb00489.x","article-title":"Cardiovascular dopamine receptors: Physiological, pharmacological and therapeutic implications","volume":"2","author":"Lokhandwala","year":"1982","journal-title":"J. Auton. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2337\/diab.25.1.6","article-title":"Norepinephrine, epinephrine, and dopamine contents of the cardiovascular system in long-term diabetics","volume":"25","author":"Neubauer","year":"1976","journal-title":"Diabetes"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3389\/fnins.2018.00591","article-title":"Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events","volume":"12","author":"Vinik","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/CIRCULATIONAHA.117.032099","article-title":"Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions","volume":"137","author":"Vijayakumar","year":"2018","journal-title":"Circulation"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/07853890008998827","article-title":"Serotonin and the heart","volume":"32","author":"Frishman","year":"2000","journal-title":"Ann. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.phrs.2011.11.009","article-title":"The risk of new onset heart failure associated with dopamine agonist use in Parkinson\u2019s disease","volume":"65","author":"Mokhles","year":"2012","journal-title":"Pharmacol. Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Fouad Shalaby, M.A., Abd El Latif, H.A., El Yamani, M., Galal, M.A., Kamal, S., Sindi, I., and Masaood, R. (2021). Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes. BMC Pharmacol. Toxicol., 22.","DOI":"10.1186\/s40360-021-00526-6"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cardfail.2010.07.246","article-title":"Impact of dopamine infusion on renal function in hospitalized heart failure patients: Results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial","volume":"16","author":"Giamouzis","year":"2010","journal-title":"J. Card. Fail."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijcard.2013.12.276","article-title":"Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial","volume":"172","author":"Triposkiadis","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jchf.2018.04.008","article-title":"Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial","volume":"6","author":"Sharma","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fnsyn.2018.00018","article-title":"The Intersection of Central Dopamine System and Stroke: Potential Avenues Aiming at Enhancement of Motor Recovery","volume":"10","author":"Gower","year":"2018","journal-title":"Front. Synaptic Neurosci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ibneur.2022.05.008","article-title":"Endogenous dopamine transmission is crucial for motor skill recovery after stroke","volume":"13","author":"Vitrac","year":"2022","journal-title":"IBRO Neurosci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S1474-4422(19)30162-0","article-title":"Dopamine for motor recovery after stroke: Where to from here?","volume":"18","author":"Stinear","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/neu.2015.17","article-title":"The effectiveness of dopamine agonists for treatment of neuropsychiatric symptoms post brain injury and stroke","volume":"27","author":"Sami","year":"2015","journal-title":"Acta Neuropsychiatr."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Villa, M., Mart\u00ednez-Vega, M., Del Pozo, A., Muneta-Arrate, I., G\u00f3mez-Soria, A., Muguruza, C., de Hoz-Rivera, M., Romero, A., Silva, L., and Callado, L.F. (2023). The Role of the Dopamine System in Post-Stroke Mood Disorders in Newborn Rats. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043229"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/eme06050","article-title":"Dopamine Augmented Rehabilitation in Stroke (DARS): A multicentre double-blind, randomised controlled trial of co-careldopa compared with placebo, in addition to routine NHS occupational and physical therapy, delivered early after stroke on functional recovery","volume":"6","author":"Ford","year":"2019","journal-title":"Effic. Mech. Eval."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(01)05966-9","article-title":"Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: A prospective, randomised, double-blind study","volume":"358","author":"Scheidtmann","year":"2001","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10571-018-0632-3","article-title":"Dopamine: Functions, Signaling, and Association with Neurological Diseases","volume":"39","author":"Klein","year":"2019","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J. Neural Transm."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1212\/WNL.15.11.980","article-title":"Dopamine and basal ganglia disorders","volume":"15","author":"Loncin","year":"1965","journal-title":"Neurology"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"V\u00e1radi, C. (2020). Clinical Features of Parkinson\u2019s Disease: The Evolution of Critical Symptoms. Biology, 9.","DOI":"10.3390\/biology9050103"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Day, J.O., and Mullin, S. (2021). The Genetics of Parkinson\u2019s Disease and Implications for Clinical Practice. Genes, 12.","DOI":"10.3390\/genes12071006"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/mds.28551","article-title":"Type 2 Diabetes as a Determinant of Parkinson\u2019s Disease Risk and Progression","volume":"36","author":"Chohan","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_86","first-page":"1585","article-title":"Diabetes Mellitus and Parkinson\u2019s Disease: A Systematic Review and Meta-Analyses","volume":"11","author":"Komici","year":"2021","journal-title":"J. Park. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41531-023-00462-8","article-title":"A nationwide cohort study on diabetes severity and risk of Parkinson disease","volume":"9","author":"Han","year":"2023","journal-title":"NPJ Park. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"735","DOI":"10.33549\/physiolres.930334","article-title":"Diabetes-induced biochemical changes in central and peripheral catecholaminergic systems","volume":"52","author":"Gallego","year":"2003","journal-title":"Physiol. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nbd.2017.04.004","article-title":"Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson\u2019s disease","volume":"109","author":"Rocha","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: Mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13024-019-0329-1","article-title":"Alpha-synuclein structure and Parkinson\u2019s disease\u2014Lessons and emerging principles","volume":"14","author":"Meade","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cca.2022.02.006","article-title":"\u03b1-Synuclein in Parkinson\u2019s disease and advances in detection","volume":"529","author":"Chen","year":"2022","journal-title":"Clin. Chim. Acta"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00018-022-04240-2","article-title":"Initiation and progression of \u03b1-synuclein pathology in Parkinson\u2019s disease","volume":"79","author":"Tofaris","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Marogianni, C., Sokratous, M., Dardiotis, E., Hadjigeorgiou, G.M., Bogdanos, D., and Xiromerisiou, G. (2020). Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson\u2019s Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228421"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Asslih, S., Damri, O., and Agam, G. (2021). Neuroinflammation as a Common Denominator of Complex Diseases (Cancer, Diabetes Type 2, and Neuropsychiatric Disorders). Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116138"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2174\/1573399812666160217122530","article-title":"Autophagy and Mitochondria in Obesity and Type 2 Diabetes","volume":"13","author":"Sarparanta","year":"2017","journal-title":"Curr. Diabetes Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"E276","DOI":"10.1152\/ajpendo.00262.2010","article-title":"\u03b1-Synuclein binds the K(ATP) channel at insulin-secretory granules and inhibits insulin secretion","volume":"300","author":"Geng","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"665348","DOI":"10.3389\/fnagi.2021.665348","article-title":"\u03b1-Synuclein Regulates Peripheral Insulin Secretion and Glucose Transport","volume":"13","author":"Wijesekara","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3389\/fnmol.2018.00465","article-title":"Could \u03b1-Synuclein Modulation of Insulin and Dopamine Identify a Novel Link Between Parkinson\u2019s Disease and Diabetes as Well as Potential Therapies?","volume":"11","author":"Yang","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fnins.2018.00073","article-title":"The Role of Insulin\/IGF-1\/PI3K\/Akt\/GSK3\u03b2 Signaling in Parkinson\u2019s Disease Dementia","volume":"12","author":"Yang","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3233\/JAD-2009-0995","article-title":"Brain insulin-like growth factor and neurotrophin resistance in Parkinson\u2019s disease and dementia with Lewy bodies: Potential role of manganese neurotoxicity","volume":"16","author":"Tong","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1871527319666200518102130","article-title":"Interlink Between Insulin Resistance and Neurodegeneration with an Update on Current Therapeutic Approaches","volume":"19","author":"Bhattamisra","year":"2020","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4103\/1673-5374.320965","article-title":"Diabetes mellitus and Parkinson\u2019s disease: Dangerous liaisons between insulin and dopamine","volume":"17","author":"Montinaro","year":"2022","journal-title":"Neural Regen. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neulet.2016.09.023","article-title":"Insulin on activation of autophagy with integrins and syndecans against MPP+-induced \u03b1-synuclein neurotoxicity","volume":"633","author":"Ramalingam","year":"2016","journal-title":"Neurosci. Lett."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1111\/bph.14471","article-title":"Therapeutic implications of how TNF links apolipoprotein E, phosphorylated tau, \u03b1-synuclein, amyloid-\u03b2 and insulin resistance in neurodegenerative diseases","volume":"175","author":"Clark","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Ruiz-Pozo, V.A., Tamayo-Trujillo, R., Cadena-Ullauri, S., Frias-Toral, E., Guevara-Ram\u00edrez, P., Paz-Cruz, E., Chapela, S., Montalv\u00e1n, M., Morales-L\u00f3pez, T., and Simancas-Racines, D. (2023). The Molecular Mechanisms of the Relationship between Insulin Resistance and Parkinson\u2019s Disease Pathogenesis. Nutrients, 15.","DOI":"10.3390\/nu15163585"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1196\/annals.1332.018","article-title":"New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists","volume":"1035","author":"Greig","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1900\/RDS.2011.8.418","article-title":"GLP-1, the gut-brain, and brain-periphery axes","volume":"8","author":"Cabou","year":"2011","journal-title":"Rev. Diabet. Stud."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jdi.12464","article-title":"Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist","volume":"7","author":"Katsurada","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"793004","DOI":"10.3389\/fnmol.2021.793004","article-title":"GLP-1 Suppresses Feeding Behaviors and Modulates Neuronal Electrophysiological Properties in Multiple Brain Regions","volume":"14","author":"Chen","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1172\/JCI78371","article-title":"Glucagon-like peptide-1 receptors in the brain: Controlling food intake and body weight","volume":"124","author":"Baggio","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-2094-5-19","article-title":"Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson\u2019s disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J. Neuroinflammation"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson\u2019s disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s11357-012-9464-0","article-title":"Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice","volume":"35","author":"Rachmany","year":"2013","journal-title":"Age"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejphar.2012.12.012","article-title":"The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain","volume":"700","author":"Parthsarathy","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jalz.2013.12.012","article-title":"Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging","volume":"10","author":"Femminella","year":"2014","journal-title":"Alzheimers Dement."},{"key":"ref_117","first-page":"345","article-title":"Is exenatide the next big thing in Parkinson\u2019s disease?","volume":"4","author":"Simuni","year":"2014","journal-title":"J. Park. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Dickson","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_119","first-page":"337","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease","volume":"4","author":"Dickson","year":"2014","journal-title":"J. Park. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","article-title":"Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer\u2019s and Parkinson\u2019s disease models","volume":"136","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"970925","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: An in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front. Neurosci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/DDDT.S348055","article-title":"The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases","volume":"16","author":"Cheng","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"175439","DOI":"10.1016\/j.ejphar.2022.175439","article-title":"Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases","volume":"938","author":"Chen","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"101979","DOI":"10.1016\/j.arr.2023.101979","article-title":"Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease","volume":"89","author":"Nowell","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_126","first-page":"e28484","article-title":"Huntington\u2019s Disease: A Clinical Review","volume":"14","author":"Andhale","year":"2022","journal-title":"Cureus"},{"key":"ref_127","first-page":"65","article-title":"The biological function of the Huntingtin protein and its relevance to Huntington\u2019s Disease pathology","volume":"5","author":"Schulte","year":"2011","journal-title":"Curr. Trends Neurol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington\u2019s disease: A clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: A clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.410310412","article-title":"Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington\u2019s disease","volume":"31","author":"Albin","year":"1992","journal-title":"Ann. Neurol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev.pa.20.040180.002533","article-title":"Chemical pathology of Huntington\u2019s disease","volume":"20","author":"Bird","year":"1980","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington\u2019s disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington\u2019s disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1073\/pnas.120166397","article-title":"Severe deficiencies in dopamine signaling in presymptomatic Huntington\u2019s disease mice","volume":"97","author":"Bibb","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0166-2236(00)01568-X","article-title":"Neuronal cell death in Huntington\u2019s disease: A potential role for dopamine","volume":"23","author":"Jakel","year":"2000","journal-title":"Trends Neurosci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1734-1140(10)70238-3","article-title":"Huntington\u2019s disease: Pathogenesis to animal models","volume":"62","author":"Kumar","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"ref_136","first-page":"1030","article-title":"Molecular Pathogenesis in Huntington\u2019s Disease","volume":"83","author":"Illarioshkin","year":"2018","journal-title":"Biochemistry"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-319-57193-5_4","article-title":"Huntington\u2019s Disease: Pathogenic Mechanisms and Therapeutic Targets","volume":"15","author":"Wright","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1399-0004.1985.tb00185.x","article-title":"Diabetes mellitus in Huntington disease","volume":"27","author":"Farrer","year":"1985","journal-title":"Clin. Genet."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3988\/jcn.2022.0212","article-title":"Increased 10-Year Prevalence of Huntington\u2019s Disease in South Korea: An Analysis of Medical Expenditure Through the National Healthcare System","volume":"19","author":"Lee","year":"2023","journal-title":"J. Clin. Neurol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3233\/JHD-170253","article-title":"Huntington\u2019s Disease and Diabetes: Chronological Sequence of its Association","volume":"6","author":"Montojo","year":"2017","journal-title":"J. Huntingt. Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/0271678X221135061","article-title":"Potential mechanisms to modify impaired glucose metabolism in neurodegenerative disorders","volume":"43","author":"McDonald","year":"2023","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"100482","DOI":"10.1016\/j.bbih.2022.100482","article-title":"Behavioral- and blood-based biomarkers for Huntington\u2019s disease: Studies on the R6\/1 mouse model with prospects for early diagnosis and monitoring of the disease","volume":"23","author":"Podlacha","year":"2022","journal-title":"Brain Behav. Immun. Health"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1007\/s12031-021-01869-9","article-title":"Mutant Huntingtin Impairs Pancreatic \u03b2-cells by Recruiting IRS-2 and Disturbing the PI3K\/AKT\/FoxO1 Signaling Pathway in Huntington\u2019s Disease","volume":"71","author":"Li","year":"2021","journal-title":"J. Mol. Neurosci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/mds.28460","article-title":"Diabetes Mellitus Is Associated With an Earlier Age of Onset of Huntington\u2019s Disease","volume":"36","author":"Ogilvie","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2174\/1567202620666230721122957","article-title":"The Metabolic Basis for Nervous System Dysfunction in Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Huntington\u2019s Disease","volume":"20","author":"Maiese","year":"2023","journal-title":"Curr. Neurovascular Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbapap.2009.12.001","article-title":"Dissecting the role of mTOR: Lessons from mTOR inhibitors","volume":"1804","author":"Dowling","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11010-020-03769-9","article-title":"Advanced glycation end-products suppress autophagy by AMPK\/mTOR signaling pathway to promote vascular calcification","volume":"471","author":"Liu","year":"2020","journal-title":"Mol. Cell. Biochem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s11010-022-04587-x","article-title":"Impairment of insulin signaling pathway PI3K\/Akt\/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: A perspective review","volume":"478","author":"Ramasubbu","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3233\/JHD-190366","article-title":"Glycation in Huntington\u2019s Disease: A Possible Modifier and Target for Intervention","volume":"8","author":"Outeiro","year":"2019","journal-title":"J. Huntingt. Dis."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/hmg\/ddv513","article-title":"AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington\u2019s disease","volume":"25","author":"Farina","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Herv\u00e1s, D., Forn\u00e9s-Ferrer, V., G\u00f3mez-Escribano, A.P., Sequedo, M.D., Peir\u00f3, C., Mill\u00e1n, J.M., and V\u00e1zquez-Manrique, R.P. (2017). Metformin intake associates with better cognitive function in patients with Huntington\u2019s disease. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179283"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0264-9","article-title":"Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease","volume":"51","author":"Sanchis","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Chang, C.C., Lin, T.C., Ho, H.L., Kuo, C.Y., Li, H.H., Korolenko, T.A., Chen, W.J., Lai, T.J., Ho, Y.J., and Lin, C.L. (2018). GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling. Int. J. Mol. Sci., 19.","DOI":"10.20944\/preprints201807.0527.v1"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"731483","DOI":"10.3389\/fphar.2021.731483","article-title":"Liraglutide Improves Cognitive and Neuronal Function in 3-NP Rat Model of Huntington\u2019s Disease","volume":"12","author":"Shawki","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2337\/db08-0799","article-title":"Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington\u2019s disease","volume":"58","author":"Martin","year":"2009","journal-title":"Diabetes"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s13311-019-00805-5","article-title":"Correction to: Vildagliptin Attenuates Huntington\u2019s Disease Through Activation of GLP-1 Receptor\/PI3K\/Akt\/BDNF Pathway in 3-Nitropropionic Acid Rat Model","volume":"17","author":"Sayed","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"118076","DOI":"10.1016\/j.lfs.2020.118076","article-title":"Dapagliflozin improves behavioral dysfunction of Huntington\u2019s disease in rats via inhibiting apoptosis-related glycolysis","volume":"257","author":"Rastanawi","year":"2020","journal-title":"Life Sci."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1064141","DOI":"10.3389\/fpsyt.2022.1064141","article-title":"ADHD in the DSM-5-TR: What has changed and what has not","volume":"13","author":"Koutsoklenis","year":"2023","journal-title":"Front. Psychiatry"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13052-023-01456-1","article-title":"The global prevalence of ADHD in children and adolescents: A systematic review and meta-analysis","volume":"49","author":"Salari","year":"2023","journal-title":"Ital. J. Pediatr."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41380-018-0070-0","article-title":"Genetics of attention deficit hyperactivity disorder","volume":"24","author":"Faraone","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"ref_161","first-page":"893","article-title":"Attention-deficit-hyperactivity disorder and reward deficiency syndrome","volume":"4","author":"Blum","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1176\/appi.ajp.2015.15020266","article-title":"Association Between ADHD and Obesity: A Systematic Review and Meta-Analysis","volume":"173","author":"Cortese","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/pedi.13195","article-title":"Dual diagnosis of type 1 diabetes mellitus and attention deficit hyperactivity disorder","volume":"22","author":"Levek","year":"2021","journal-title":"Pediatr. Diabetes"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Garcia-Argibay, M., Li, L., Du Rietz, E., Zhang, L., Yao, H., Jendle, J., Ramos-Quiroga, J.A., Ribas\u00e9s, M., Chang, Z., and Brikell, I. (2023). The association between type 2 diabetes and attention- deficit\/hyperactivity disorder: A systematic review, meta-analysis, and population-based sibling study. Neurosci. Biobehav. Rev., 147.","DOI":"10.1016\/j.neubiorev.2023.105076"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.neubiorev.2021.10.035","article-title":"Non-mental diseases associated with ADHD across the lifespan: Fidgety Philipp and Pippi Longstocking at risk of multimorbidity?","volume":"132","author":"Vasquez","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e20171645","DOI":"10.1542\/peds.2017-1645","article-title":"Attention-Deficit\/Hyperactivity Disorder and Very Preterm\/Very Low Birth Weight: A Meta-analysis","volume":"141","author":"Franz","year":"2018","journal-title":"Pediatrics"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for Medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr. Pract."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jad.2022.10.016","article-title":"ADHD and eating disorders in childhood and adolescence: An updated minireview","volume":"321","author":"Villa","year":"2023","journal-title":"J. Affect. Disord."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/eat.22643","article-title":"The risk of eating disorders comorbid with attention-deficit\/hyperactivity disorder: A systematic review and meta-analysis","volume":"49","author":"Nazar","year":"2016","journal-title":"Int. J. Eat. Disord."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Catal\u00e1-L\u00f3pez, F., Hutton, B., N\u00fa\u00f1ez-Beltr\u00e1n, A., Page, M.J., Ridao, M., Mac\u00edas Saint-Gerons, D., Catal\u00e1, M.A., Tabar\u00e9s-Seisdedos, R., and Moher, D. (2017). The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180355"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1517\/14728222.6.5.601","article-title":"The role of dopamine in motivation for food in humans: Implications for obesity","volume":"6","author":"Wang","year":"2002","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/oby.20574","article-title":"Methylphenidate decreases fat and carbohydrate intake in obese teenagers","volume":"22","author":"Danilovich","year":"2014","journal-title":"Obesity"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ajcn\/86.2.308","article-title":"Methylphenidate reduces energy intake and dietary fat intake in adults: A mechanism of reduced reinforcing value of food?","volume":"86","author":"Goldfield","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.mehy.2007.10.012","article-title":"Does dopaminergic reward system contribute to explaining comorbidity obesity and ADHD?","volume":"70","author":"Liu","year":"2008","journal-title":"Med. Hypotheses"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e20931","DOI":"10.1097\/MD.0000000000020931","article-title":"Methylphenidate has mild hyperglycemic and hypokalemia effects and increases leukocyte and neutrophil counts","volume":"99","author":"Charach","year":"2020","journal-title":"Medicine"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fnins.2013.00181","article-title":"The central GLP-1: Implications for food and drug reward","volume":"7","author":"Skibicka","year":"2013","journal-title":"Front. Neurosci."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2337\/db14-0849","article-title":"GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans","volume":"63","author":"IJzerman","year":"2014","journal-title":"Diabetes"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.physbeh.2014.02.026","article-title":"Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior","volume":"136","author":"Anderberg","year":"2014","journal-title":"Physiol. Behav."},{"key":"ref_179","first-page":"290","article-title":"Behavioral Addiction versus Substance Addiction: Correspondence of Psychiatric and Psychological Views","volume":"3","author":"Alavi","year":"2012","journal-title":"Int. J. Prev. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.addbeh.2008.10.021","article-title":"Early-onset drug use and risk for drug dependence problems","volume":"34","author":"Chen","year":"2009","journal-title":"Addict. Behav."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1556\/2006.4.2015.037","article-title":"Smartphone use and smartphone addiction among young people in Switzerland","volume":"4","author":"Haug","year":"2015","journal-title":"J. Behav. Addict."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/alcalc\/agaa068","article-title":"Mechanisms of Alcohol Addiction: Bridging Human and Animal Studies","volume":"55","author":"Kramer","year":"2020","journal-title":"Alcohol Alcohol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/14622200500055251","article-title":"Nicotine addiction through a neurogenomic prism: Ethics, public health, and smoking","volume":"7","author":"Caron","year":"2005","journal-title":"Nicotine Tob. Res."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s13181-015-0521-9","article-title":"Chronic Pain, Chronic Opioid Addiction: A Complex Nexus","volume":"12","author":"Salsitz","year":"2016","journal-title":"J. Med. Toxicol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2021.08.001","article-title":"What Is Addiction? History, Terminology, and Core Concepts","volume":"106","author":"Olsen","year":"2022","journal-title":"Med. Clin. N. Am."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000324065","article-title":"Addiction and brain reward and antireward pathways","volume":"30","author":"Gardner","year":"2011","journal-title":"Adv. Psychosom. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2174\/1871530322666220127114326","article-title":"Neuroendocrine Modulation of Food Intake and Eating Behavior","volume":"22","author":"Iovino","year":"2022","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.yfrne.2009.10.004","article-title":"Metabolic hormones, dopamine circuits, and feeding","volume":"31","author":"Narayanan","year":"2010","journal-title":"Front. Neuroendocrinol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1017\/S0029665119001162","article-title":"Food addiction, eating addiction and eating disorders","volume":"79","author":"Hauck","year":"2020","journal-title":"Proc. Nutr. Soc."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Novelle, M.G., and Di\u00e9guez, C. (2018). Food Addiction and Binge Eating: Lessons Learned from Animal Models. Nutrients, 10.","DOI":"10.3390\/nu10010071"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrn.2017.130","article-title":"The dopamine motive system: Implications for drug and food addiction","volume":"18","author":"Volkow","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nrn3939","article-title":"The dopamine theory of addiction: 40 years of highs and lows","volume":"16","author":"Nutt","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Constant, A., Moirand, R., Thibault, R., and Val-Laillet, D. (2020). Meeting of Minds around Food Addiction: Insights from Addiction Medicine, Nutrition, Psychology, and Neurosciences. Nutrients, 12.","DOI":"10.3390\/nu12113564"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"106475","DOI":"10.1016\/j.appet.2023.106475","article-title":"Food addiction, hormones and blood biomarkers in humans: A systematic literature review","volume":"183","author":"Bliokas","year":"2023","journal-title":"Appetite"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e22254","DOI":"10.1002\/syn.22254","article-title":"Dopamine receptor and dopamine transporter in obesity: A meta-analysis","volume":"77","author":"Pak","year":"2023","journal-title":"Synapse"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tics.2010.11.001","article-title":"Reward, dopamine and the control of food intake: Implications for obesity","volume":"15","author":"Volkow","year":"2011","journal-title":"Trends Cogn. Sci."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e00521","DOI":"10.34172\/jrhs.2021.63","article-title":"Diet Therapeutics Interventions for Obesity: A Systematic Review and Network Meta-Analysis","volume":"21","author":"Morsali","year":"2021","journal-title":"J. Res. Health Sci."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000515381","article-title":"European Guidelines for Obesity Management in Adults with a Very Low-Calorie Ketogenic Diet: A Systematic Review and Meta-Analysis","volume":"14","author":"Muscogiuri","year":"2021","journal-title":"Obes. Facts"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"112121","DOI":"10.1016\/j.exger.2023.112121","article-title":"Mediterranean diet in the management and prevention of obesity","volume":"174","author":"Dominguez","year":"2023","journal-title":"Exp. Gerontol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jada.2007.07.017","article-title":"Weight-loss outcomes: A systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up","volume":"107","author":"Franz","year":"2007","journal-title":"J. Am. Diet. Assoc."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"van Baak, M.A., and Mariman, E.C.M. (2019). Dietary Strategies for Weight Loss Maintenance. Nutrients, 11.","DOI":"10.3390\/nu11081916"},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Flore, G., Preti, A., Carta, M.G., Deledda, A., Fosci, M., Nardi, A.E., Loviselli, A., and Velluzzi, F. (2022). Weight Maintenance after Dietary Weight Loss: Systematic Review and Meta-Analysis on the Effectiveness of Behavioural Intensive Intervention. Nutrients, 14.","DOI":"10.3390\/nu14061259"},{"key":"ref_203","first-page":"210524","article-title":"Mechanisms of Weight Regain following Weight Loss","volume":"2013","author":"Blomain","year":"2013","journal-title":"ISRN Obes."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41574-018-0148-4","article-title":"Mechanisms of weight regain after weight loss\u2014The role of adipose tissue","volume":"15","author":"Mariman","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2021.01.002","article-title":"Mechanisms of weight regain","volume":"93","author":"Busetto","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s42255-023-00816-9","article-title":"Brain responses to nutrients are severely impaired and not reversed by weight loss in humans with obesity: A randomized crossover study","volume":"5","author":"Schrantee","year":"2023","journal-title":"Nat. Metab."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"114236","DOI":"10.1016\/j.physbeh.2023.114236","article-title":"Metabolic hormone action in the VTA: Reward-directed behavior and mechanistic insights","volume":"268","author":"Geisler","year":"2023","journal-title":"Physiol. Behav."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Rezitis, J., Herzog, H., and Ip, C.K. (2022). Neuropeptide Y interaction with dopaminergic and serotonergic pathways: Interlinked neurocircuits modulating hedonic eating behaviours. Prog. Neuropsychopharmacol. Biol. Psychiatry, 113.","DOI":"10.1016\/j.pnpbp.2021.110449"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2826.2009.01896.x","article-title":"Ghrelin and dopamine: New insights on the peripheral regulation of appetite","volume":"21","author":"Abizaid","year":"2009","journal-title":"J. Neuroendocrinol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.neuroscience.2009.03.086","article-title":"Peripherally administered ghrelin induces bimodal effects on the mesolimbic dopamine system depending on food-consumptive states","volume":"161","author":"Kawahara","year":"2009","journal-title":"Neuroscience"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.neuropharm.2012.11.022","article-title":"Food reward-sensitive interaction of ghrelin and opioid receptor pathways in mesolimbic dopamine system","volume":"67","author":"Kawahara","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1210\/en.2011-1606","article-title":"Ghrelin interacts with neuropeptide Y Y1 and opioid receptors to increase food reward","volume":"153","author":"Skibicka","year":"2012","journal-title":"Endocrinology"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"112986","DOI":"10.1016\/j.physbeh.2020.112986","article-title":"Lateral hypothalamic area neuropeptides modulate ventral tegmental area dopamine neurons and feeding","volume":"223","author":"Leinninger","year":"2020","journal-title":"Physiol. Behav."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.psyneuen.2019.02.006","article-title":"Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents","volume":"103","author":"Kalafateli","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice","volume":"149","author":"Reddy","year":"2015","journal-title":"Physiol. Behav."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"112466","DOI":"10.1016\/j.celrep.2023.112466","article-title":"GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity","volume":"42","author":"Falk","year":"2023","journal-title":"Cell Rep."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1523\/JNEUROSCI.0115-14.2014","article-title":"Glucagon-like peptide-1 receptor activation in the nucleus accumbens core suppresses feeding by increasing glutamatergic AMPA\/kainate signaling","volume":"34","author":"Ortinski","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_218","unstructured":"Kintscher, U. (2012). Appetite Control, Springer."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.npp.1301155","article-title":"Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice","volume":"32","author":"Billes","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/sj.npp.1301526","article-title":"Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis","volume":"33","author":"Billes","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fendo.2020.00152","article-title":"D2-Like Receptors Mediate Dopamine-Inhibited Insulin Secretion via Ion Channels in Rat Pancreatic \u03b2-Cells","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2337\/db21-0644","article-title":"Dopamine Negatively Regulates Insulin Secretion Through Activation of D1-D2 Receptor Heteromer","volume":"71","author":"Uefune","year":"2022","journal-title":"Diabetes"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41398-020-01171-z","article-title":"Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors","volume":"11","author":"Aslanoglou","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/s41380-018-0344-6","article-title":"New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion","volume":"25","author":"Farino","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"E1367","DOI":"10.1152\/ajpendo.00413.2013","article-title":"The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA\/kainate receptors","volume":"305","author":"Ortinski","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_226","unstructured":"(2023, September 25). Available online: https:\/\/diabetesjournals.org\/care\/article\/46\/Supplement_1\/S140\/148057\/9-Pharmacologic-Approaches-to-Glycemic-Treatment."},{"key":"ref_227","unstructured":"(2023, September 25). Available online: https:\/\/diabetesjournals.org\/care\/article\/34\/4\/789\/38811\/Bromocriptine-A-Sympatholytic-D2-Dopamine-Agonist."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"104771","DOI":"10.1016\/j.isci.2022.104771","article-title":"Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine","volume":"25","author":"Aslanoglou","year":"2022","journal-title":"iScience"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2337\/dc09-2009","article-title":"Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes","volume":"33","author":"Gaziano","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/WCO.0000000000001166","article-title":"Parkinson\u2019s disease\u2014Current treatment","volume":"36","author":"Wang","year":"2023","journal-title":"Curr. Opin. Neurol."},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Dietrichs, E., Alves, G., Benjaminsen, E., Johansen, K.K., and Tysnes, O.B. (2023). Treatment of motor symptoms in Parkinson\u2019s disease. Tidsskr. Nor Laegeforen., 143.","DOI":"10.4045\/tidsskr.22.0804"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/WNL.51.2_Suppl_2.S10","article-title":"Do dopamine agonists provide neuroprotection?","volume":"51","author":"Yamamoto","year":"1998","journal-title":"Neurology"},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Cacabelos, R. (2017). Parkinson\u2019s Disease: From Pathogenesis to Pharmacogenomics. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18030551"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00702-023-02647-0","article-title":"Role of dopamine agonists in Parkinson\u2019s disease therapy","volume":"130","author":"Woitalla","year":"2023","journal-title":"J. Neural Transm."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/CPJ.0b013e318278be9b","article-title":"Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease","volume":"2","author":"Weiss","year":"2012","journal-title":"Neurol. Clin. Pract."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/jdi.12892","article-title":"Brown rice-specific \u03b3-oryzanol as a promising prophylactic avenue to protect against diabetes mellitus and obesity in humans","volume":"10","author":"Masuzaki","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.2337\/db11-1767","article-title":"Brown rice and its component, \u03b3-oryzanol, attenuate the preference for high-fat diet by decreasing hypothalamic endoplasmic reticulum stress in mice","volume":"61","author":"Kozuka","year":"2012","journal-title":"Diabetes"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1210\/en.2014-1748","article-title":"\u03b3-Oryzanol protects pancreatic \u03b2-cells against endoplasmic reticulum stress in male mice","volume":"156","author":"Kozuka","year":"2015","journal-title":"Endocrinology"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1111\/bph.13236","article-title":"A novel insulinotropic mechanism of whole grain-derived \u03b3-oryzanol via the suppression of local dopamine D2 receptor signalling in mouse islet","volume":"172","author":"Kozuka","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neuro.2015.09.003","article-title":"Effectiveness of \u03b3-oryzanol in reducing neuromotor deficits, dopamine depletion and oxidative stress in a Drosophila melanogaster model of Parkinson\u2019s disease induced by rotenone","volume":"51","author":"Araujo","year":"2015","journal-title":"Neurotoxicology"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2174\/1874467214666210126113324","article-title":"The Beneficial Effect of Rice Bran Extract Against Rotenone-Induced Experimental Parkinson\u2019s Disease in Rats","volume":"14","author":"Kumar","year":"2021","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: Update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/01677063.2015.1067203","article-title":"AMPK-mediated regulation of neuronal metabolism and function in brain diseases","volume":"29","author":"Liu","year":"2015","journal-title":"J. Neurogenet."},{"key":"ref_244","first-page":"161","article-title":"Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson\u2019s Disease","volume":"8","author":"Curry","year":"2018","journal-title":"J. Park. Dis."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3389\/fendo.2018.00400","article-title":"The Therapeutic Potential of Metformin in Neurodegenerative Diseases","volume":"9","author":"Rotermund","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"108173","DOI":"10.1016\/j.neuropharm.2020.108173","article-title":"Metformin regulates astrocyte reactivity in Parkinson\u2019s disease and normal aging","volume":"175","author":"Ryu","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_247","unstructured":"(2023, September 05). Available online: https:\/\/www.ncbi.nlm.nih.gov\/gene\/586."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"26438","DOI":"10.1073\/pnas.2009838117","article-title":"Metformin rescues Parkinson\u2019s disease phenotypes caused by hyperactive mitochondria","volume":"117","author":"Mor","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"104593","DOI":"10.1016\/j.phrs.2019.104593","article-title":"Emerging neuroprotective effect of metformin in Parkinson\u2019s disease: A molecular crosstalk","volume":"152","author":"Paudel","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1007\/s11095-017-2199-y","article-title":"Metformin\u2014A Future Therapy for Neurodegenerative Diseases: Theme: Drug Discovery, Development and Delivery in Alzheimer\u2019s Disease Guest Editor: Davide Brambilla","volume":"34","author":"Sikora","year":"2017","journal-title":"Pharm. Res."},{"key":"ref_251","doi-asserted-by":"crossref","unstructured":"Huang, K.H., Chang, Y.L., Gau, S.Y., Tsai, T.H., and Lee, C.Y. (2022). Dose-Response Association of Metformin with Parkinson\u2019s Disease Odds in Type 2 Diabetes Mellitus. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14050946"},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Alrouji, M., Al-Kuraishy, H.M., Al-Gareeb, A.I., Ashour, N.A., Jabir, M.S., Negm, W.A., and Batiha, G.E. (2023). Metformin role in Parkinson\u2019s disease: A double-sword effect. Mol. Cell. Biochem.","DOI":"10.1007\/s11010-023-04771-7"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1017\/S1041610211002511","article-title":"Cognitive impairment and vitamin B12: A review","volume":"24","author":"Moore","year":"2012","journal-title":"Int. Psychogeriatr."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1475-2840-6-20","article-title":"Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes","volume":"6","author":"Hanefeld","year":"2007","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Wang, H. (2021). MicroRNAs, Parkinson\u2019s Disease, and Diabetes Mellitus. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062953"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1358\/dnp.2004.17.4.829049","article-title":"Antiinflammatory properties of PPARgamma agonists following ischemia","volume":"17","author":"Sundararajan","year":"2004","journal-title":"Drug News Perspect."},{"key":"ref_257","first-page":"160","article-title":"New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer)","volume":"38","author":"Tjokroprawiro","year":"2006","journal-title":"Acta Med. Indones."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2741\/2802","article-title":"Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists","volume":"13","author":"Kapadia","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.expneurol.2012.09.003","article-title":"Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: A preclinical stroke trial","volume":"238","author":"Culman","year":"2012","journal-title":"Exp. Neurol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1471-4159.2010.06999.x","article-title":"Administration of thiazolidinediones for neuroprotection in ischemic stroke: A pre-clinical systematic review","volume":"115","author":"White","year":"2010","journal-title":"J. Neurochem."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.5551\/jat.30007","article-title":"Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study","volume":"22","author":"Tanaka","year":"2015","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after Ischemic Stroke or Transient Ischemic Attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12933-017-0617-4","article-title":"Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials","volume":"16","author":"Visseren","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jcpt.12808","article-title":"Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer\u2019s disease","volume":"44","author":"Jojo","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"9860855","DOI":"10.1155\/2022\/9860855","article-title":"Neuroprotective and Anti-inflammatory Effects of Pioglitazone on Traumatic Brain Injury","volume":"2022","author":"Zamanian","year":"2022","journal-title":"Mediat. Inflamm."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.2147\/DDDT.S367229","article-title":"Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature","volume":"16","author":"Alhowail","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1749-6632.2003.tb07478.x","article-title":"The role of glial reaction and inflammation in Parkinson\u2019s disease","volume":"991","author":"Hirsch","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1471-4159.2003.02210.x","article-title":"Protection by pioglitazone in the MPTP model of Parkinson\u2019s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation","volume":"88","author":"Dehmer","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/157015907780077123","article-title":"Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson\u2019s Disease","volume":"5","author":"Randy","year":"2007","journal-title":"Curr. Neuropharmacol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12640-012-9342-7","article-title":"Modulating microglia activity with PPAR-\u03b3 agonists: A promising therapy for Parkinson\u2019s disease?","volume":"23","author":"Carta","year":"2013","journal-title":"Neurotox. Res."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1474-4422(21)00043-0","article-title":"Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer\u2019s disease (TOMMORROW): A prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Burns","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"666958","DOI":"10.3389\/fnins.2021.666958","article-title":"Reassessment of Pioglitazone for Alzheimer\u2019s Disease","volume":"15","author":"Saunders","year":"2021","journal-title":"Front. Neurosci."},{"key":"ref_273","first-page":"731","article-title":"Peripheral Biomarkers of Parkinson\u2019s Disease Progression and Pioglitazone Effects","volume":"5","author":"Simon","year":"2015","journal-title":"J. Park. Dis."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1007\/s10072-020-04494-3","article-title":"Thiazolidinedione use is associated with reduced risk of Parkinson\u2019s disease in patients with diabetes: A meta-analysis of real-world evidence","volume":"41","author":"Hussain","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jocn.2022.10.023","article-title":"Pioglitazone use is associated with reduced risk of Parkinson\u2019s disease in patients with diabetes: A systematic review and meta-analysis","volume":"106","author":"Chen","year":"2022","journal-title":"J. Clin. Neurosci."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/pds.5448","article-title":"Association between different diabetes medication classes and risk of Parkinson\u2019s disease in people with diabetes","volume":"31","author":"Sunnarborg","year":"2022","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_277","doi-asserted-by":"crossref","unstructured":"NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators (2015). Pioglitazone in early Parkinson\u2019s disease: A phase 2, multicentre, double-blind, randomised trial. Lancet Neurol., 14, 795\u2013803. Erratum in Lancet Neurol. 2015, 14, 979.","DOI":"10.1016\/S1474-4422(15)00144-1"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.beem.2009.03.004","article-title":"Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)","volume":"23","author":"Thornberry","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: Physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"295","DOI":"10.6026\/97320630019295","article-title":"An update on diagnosis and therapeutics for type-2 diabetes mellitus","volume":"19","author":"Shyamaladevi","year":"2023","journal-title":"Bioinformation"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jnc.13087","article-title":"Neuroprotective effects of vildagliptin in rat rotenone Parkinson\u2019s disease model: Role of RAGE-NF\u03baB and Nrf2-antioxidant signaling pathways","volume":"133","author":"Abdelsalam","year":"2015","journal-title":"J. Neurochem."},{"key":"ref_282","doi-asserted-by":"crossref","unstructured":"Pariyar, R., Bastola, T., Lee, D.H., and Seo, J. (2022). Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042388"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10787-017-0331-6","article-title":"Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson\u2019s disease","volume":"25","author":"Badawi","year":"2017","journal-title":"Inflammopharmacology"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/01616412.2018.1474840","article-title":"Sitagliptin rescues memory deficits in Parkinsonian rats via upregulating BDNF to prevent neuron and dendritic spine loss","volume":"40","author":"Li","year":"2018","journal-title":"Neurol Res."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4103\/ijp.IJP_384_20","article-title":"Neuroprotective effects of linagliptin in a rotenone-induced rat model of Parkinson\u2019s disease","volume":"54","author":"Abhangi","year":"2022","journal-title":"Indian J. Pharmacol."},{"key":"ref_286","first-page":"1818","article-title":"Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson\u2019s disease","volume":"18","author":"Yu","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuropharm.2014.10.007","article-title":"Saxagliptin: A novel antiparkinsonian approach","volume":"89","author":"Nassar","year":"2015","journal-title":"Neuropharmacology"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/jphp.12936","article-title":"Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats","volume":"70","author":"Turnes","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/mds.26734","article-title":"Reduced incidence of Parkinson\u2019s disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study","volume":"31","author":"Svenningsson","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson\u2019s disease: A cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neurobiolaging.2020.01.004","article-title":"Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging","volume":"89","author":"Lietzau","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awab015","article-title":"Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson\u2019s disease","volume":"144","author":"Jeong","year":"2021","journal-title":"Brain"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"678649","DOI":"10.3389\/fneur.2021.678649","article-title":"Association Between Diabetes Medications and the Risk of Parkinson\u2019s Disease: A Systematic Review and Meta-Analysis","volume":"12","author":"Qin","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_294","doi-asserted-by":"crossref","unstructured":"Wang, S.Y., Wu, S.L., Chen, T.C., and Chuang, C.S. (2020). Antidiabetic Agents for Treatment of Parkinson\u2019s Disease: A Meta-Analysis. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17134805"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"110170","DOI":"10.1016\/j.intimp.2023.110170","article-title":"A novel protective modality against rotenone-induced Parkinson\u2019s disease: A pre-clinical study with dulaglutide","volume":"119","author":"Khalaf","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41366-023-01337-x","article-title":"Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: A meta-analysis of randomized controlled trials","volume":"47","author":"Padrao","year":"2023","journal-title":"Int. J. Obes."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"920541","DOI":"10.3389\/fendo.2022.920541","article-title":"Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis","volume":"13","author":"Lisco","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"e2231","DOI":"10.1002\/brb3.2231","article-title":"The GLP-1\/GIP dual-receptor agonist DA5-CH inhibits the NF-\u03baB inflammatory pathway in the MPTP mouse model of Parkinson\u2019s disease more effectively than the GLP-1 single-receptor agonist NLY01","volume":"11","author":"Lv","year":"2021","journal-title":"Brain Behav."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2015.09.035","article-title":"A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson\u2019s disease by increasing expression of BNDF","volume":"1634","author":"Ji","year":"2016","journal-title":"Brain Res."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/WNR.0000000000000548","article-title":"A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson\u2019s disease by reducing chronic inflammation in the brain","volume":"27","author":"Cao","year":"2016","journal-title":"Neuroreport"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"955258","DOI":"10.3389\/fnsyn.2022.955258","article-title":"Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"14","year":"2022","journal-title":"Front. Synaptic Neurosci."},{"key":"ref_303","doi-asserted-by":"crossref","unstructured":"Salameh, T.S., Rhea, E.M., Talbot, K., and Banks, W.A. (2023). Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics. Biochem Pharmacol., 180, Erratum in Biochem. Pharmacol. 2023, 210, 115474.","DOI":"10.1016\/j.bcp.2023.115474"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"Hompesch","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2010.512","article-title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans","volume":"79","author":"List","year":"2011","journal-title":"Kidney Int. Suppl."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_310","doi-asserted-by":"crossref","unstructured":"Lin, K.J., Wang, T.J., Chen, S.D., Lin, K.L., Liou, C.W., Lan, M.Y., Chuang, Y.C., Chuang, J.H., Wang, P.W., and Lee, J.J. (2021). Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease-Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors. Antioxidants, 10.","DOI":"10.3390\/antiox10121935"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1021\/acschemneuro.0c00722","article-title":"Targeting ROS-Dependent AKT\/GSK-3\u03b2\/NF-\u03baB and DJ-1\/Nrf2 Pathways by Dapagliflozin Attenuates Neuronal Injury and Motor Dysfunction in Rotenone-Induced Parkinson\u2019s Disease Rat Model","volume":"12","author":"Arab","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jsps.2022.03.005","article-title":"Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of \u03b1-synuclein and Parkin levels in rotenone-induced Parkinson\u2019s disease in rats","volume":"30","author":"Ahmed","year":"2022","journal-title":"Saudi Pharm. J."},{"key":"ref_313","doi-asserted-by":"crossref","unstructured":"Motawi, T.K., Al-Kady, R.H., Abdelraouf, S.M., and Senousy, M.A. (2022). Empagliflozin alleviates endoplasmic reticulum stress and augments autophagy in rotenone-induced Parkinson\u2019s disease in rats: Targeting the GRP78\/PERK\/eIF2\u03b1\/CHOP pathway and miR-211-5p. Chem. Biol. Interact., 362.","DOI":"10.1016\/j.cbi.2022.110002"},{"key":"ref_314","first-page":"148536","article-title":"Sodium-dependent Glucose Co-Transporter-2 Inhibitor Empagliflozin Exerts Neuroprotective Effects in Rotenone-Induced Parkinson\u2019s Disease Model in Zebrafish; Mechanism Involving Ketogenesis and Autophagy","volume":"15","author":"Beler","year":"2023","journal-title":"Brain Res."},{"key":"ref_315","first-page":"1","article-title":"Repurposing the inhibitors of MMP-9 and SGLT-2 against ubiquitin specific protease 30 in Parkinson\u2019s disease: Computational modelling studies","volume":"3","author":"Alshehri","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"747620","DOI":"10.3389\/fcvm.2021.747620","article-title":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","volume":"8","author":"Mui","year":"2021","journal-title":"Front Cardiovasc. Med."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"20406223221086996","DOI":"10.1177\/20406223221086996","article-title":"Sodium-glucose cotransporter 2 inhibitors and neurological disorders: A scoping review","volume":"13","author":"Tharmaraja","year":"2022","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"37A","DOI":"10.1210\/jcem.97.3.zeg37a","article-title":"Type 2 Diabetes and Insulin Secretagogues","volume":"97","author":"Inzucchi","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1111\/jgs.18397","article-title":"Association of sulfonylureas with the risk of dementia: A population-based cohort study","volume":"71","author":"Wu","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/DMSO.S7606","article-title":"Amantadine reduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: Central plus peripheral nervous system mechanisms","volume":"2","author":"Lechin","year":"2009","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_321","doi-asserted-by":"crossref","unstructured":"Sanni, O., and Terre\u2019Blanche, G. (2023). Dual A1 and A2A adenosine receptor antagonists, methoxy substituted 2-benzylidene-1-indanone, suppresses intestinal postprandial glucose and attenuates hyperglycaemia in fructose-streptozotocin diabetic rats. BMC Endocr. Disord., 23.","DOI":"10.1186\/s12902-023-01354-x"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1172\/JCI70678","article-title":"Lorcaserin and pimavanserin: Emerging selectivity of serotonin receptor subtype-targeted drugs","volume":"123","author":"Meltzer","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40263-023-01022-7","article-title":"Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia","volume":"37","author":"Meyer","year":"2023","journal-title":"CNS Drugs"},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"e2129397","DOI":"10.1001\/jamanetworkopen.2021.29397","article-title":"Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial","volume":"4","author":"Coffey","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_325","doi-asserted-by":"crossref","unstructured":"Huntington Study Group, Frank, S., Testa, C.M., Stamler, D., Kayson, E., Davis, C., Edmondson, M.C., Kinel, S., Leavitt, B., and Oakes, D. (2016). Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA, 316, 40\u201350.","DOI":"10.1001\/jama.2016.8655"},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1196\/annals.1367.017","article-title":"Serotonin and norepinephrine reuptake inhibition and eating behavior","volume":"1083","author":"Hainer","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_327","first-page":"e350","article-title":"Opioid use disorder and type 2 diabetes mellitus: Effect of participation in buprenorphine-naloxone substitution programs on glycemic control","volume":"63","author":"Tilbrook","year":"2017","journal-title":"Can. Fam. Physician"},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1742-7843.2011.00699.x","article-title":"\u03b12-adrenoceptor regulation of blood glucose homeostasis","volume":"108","author":"Fagerholm","year":"2011","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2337\/diacare.27.3.847","article-title":"Naltrexone improves blood glucose control in type 1 diabetic women with severe and chronic eating disorders","volume":"27","author":"Raingeard","year":"2004","journal-title":"Diabetes Care"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/11\/2993\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:18:57Z","timestamp":1760131137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/11\/2993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":329,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["biomedicines11112993"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines11112993","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]}}}